Baijin Life Science Holdings Limited
MNNGF
$0.08
$0.000.00%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 183.15% | 183.01% | -22.40% | -22.49% | -49.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 183.15% | 183.01% | -22.40% | -22.49% | -49.61% |
| Cost of Revenue | 209.97% | 209.82% | -56.70% | -56.75% | -52.84% |
| Gross Profit | 121.46% | 121.33% | 312.92% | 312.68% | -40.17% |
| SG&A Expenses | 79.00% | 78.91% | 39.99% | 39.83% | 2,568.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -499.22% | -499.22% | 97.90% | 97.90% | -127.68% |
| Total Operating Expenses | 151.74% | 151.62% | -30.60% | -30.68% | -27.88% |
| Operating Income | 119.82% | 119.81% | 52.67% | 52.72% | -126.45% |
| Income Before Tax | 130.59% | 130.58% | -293.56% | -293.08% | -122.66% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.69% | 17.73% | -294.55% | -294.07% | -122.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -169.55% | -169.49% | -225.07% | -224.73% | -122.66% |
| EBIT | 119.82% | 119.81% | 52.67% | 52.72% | -126.45% |
| EBITDA | 181.70% | 181.66% | 56.61% | 56.66% | -125.37% |
| EPS Basic | -200.00% | -200.00% | -150.00% | -150.00% | -116.67% |
| Normalized Basic EPS | -300.00% | -300.00% | -200.00% | -200.00% | -114.29% |
| EPS Diluted | -200.00% | -200.00% | -150.00% | -150.00% | -116.67% |
| Normalized Diluted EPS | -300.00% | -300.00% | -200.00% | -200.00% | -114.29% |
| Average Basic Shares Outstanding | 6.25% | 6.25% | 1.53% | 1.53% | 12.96% |
| Average Diluted Shares Outstanding | 6.25% | 6.25% | 1.53% | 1.53% | 12.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |